

16 March 2023 EMA/MB/948302/2022 Management Board

Agenda for the 119 meeting of the Management Board Held on 16 March 2023, WebEx (09:00 – 15:00)

Chairperson: Lorraine Nolan

Item			
1.	Draft agenda	For adoption, EMA/MB/948302/2022*	
2.	Declarations of competing interests related to the current agenda	Oral report	
3.	Minutes from the 118 th meeting, held on 14-15 December 2022 to be adopted via written procedure	EMA/MB/17597/2023*	
Α	Points for automatic adoption		
A.1	Update on impact of inflation rate on delegate reimbursement rules	For information & adoption, EMA/MB/74833/2023; EMA/MB/279597/2018, rev.4*	
В	Points for discussion		
B.1	Highlights of the Executive Director	Oral report	
B.2	Report from the European Commission	Oral report	
B.3	EMA Annual Report 2022	For information, EMA/MB/70226/2023; For adoption, EMA/46734/2023*	
B.4	2022 EMA Annual Report on Independence	For information, EMA/MB/88253/2023; For endorsement, EMA/2588/2023*	
B.5	Revised implementing rules to the Fee Regulation as of 1 April 2023	For information, EMA/MB/700128/2022; For adoption, EMA/MB/622516/2022*	
B.6	Review of activities of the Working Parties of the EMA - Update from the MB Review Group	For information, EMA/MB/94231/2023	
B.7	3rd EC report on the performance of pharmacovigilancetasks by the EU Member States and the EMA (2019-2022)update on status of preparation and next steps	For information, EMA/MB/87854/2023	
B.8	Report from the CVMP Chair	Oral report	

Official addressDomenico Scarlattilaan 6 • 1083 HS Amsterdam • The NetherlandsAddress for visits and deliveriesRefer to www.ema.europa.eu/how-to-find-usSend us a questionGo to www.ema.europa.eu/contactTelephone +31 (0)88 781 6000



An agency of the European Union

© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.

B.9	Update on Agile transformation and Network portfolio	For information,
		EMA/MB/94296/2023;
		EMA/93979/2023
B.10	Report to the Management Board on the implementation of	For information,
	EU IT systems required by the Clinical Trial Regulation	EMA/MB/66824/2023;
		EMA/76948/2023
B.11	Update on Accelerating Clinical Trials in the EU (ACT EU)	Oral report
B.12	Big Data Steering Group progress report	Oral report
С	Points for information only**	
C.1	Outcome of written procedures finalised during the period	For information,
	from 06 December 2022 to 08 March 2023	EMA/MB/948919/2022*
C.2	Feedback from the Heads of Medicines Agencies	
C.3	2022 Annual Report on EudraVigilance for the European	For information,
0.0	Parliament, the Council and the Commission Reporting	EMA/MB/66824/2023;
	period: 1 January to 31 December 2022	EMA/900566/2022*
C.4		For information,
C.4	Fifteenth six-monthly report on <i>ex ante</i> and retroactive	,
	evaluation of projects for the period 1 July to 31 December	EMA/MB/26674/2023;
	2022	EMA/26675/2023
C.5	EMA working document on buildings	For information,
		EMA/MB/72500/2023
		EMA/71459/2023
C.6	Summary of transfers of appropriations in budget	For information,
		EMA/MB/99789/2023
C.7	ECA Annual report on EU agencies for the financial year	For information
	2021	
	https://www.eca.europa.eu/Lists/ECADocuments/AGENCIES 2021	
	/AGENCIES 2021 EN.pdf	

* Documents marked with a star * are intended for publication on the external website. ** Documents in Additional documents for information section are not intended for discussion unless specifically requested.